Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Billiet

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
European Journal of Gastroenterology & Hepatology|February 21, 2018
The operative risk and natural history after the diagnosis of ileal penetrating Crohn's diseasePeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
European Journal of Gastroenterology & Hepatology|September 8, 2016
Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatmentLucas Wauters, Thomas Billiet, Konstantinos Papamichael, et al.
Scandinavian Journal of Gastroenterology|June 17, 2017
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's diseaseThomas Billiet, Isabelle Cleynen, Vera Ballet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of ThiopurinesHaggai Bar-Yoseph, Matti Waterman, Ronit Almog, et al.
Journal of Crohn'S & Colitis|September 10, 2015
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's DiseaseThomas Billiet, Konstantinos Papamichael, Magali de Bruyn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 19, 2015
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative ColitisKonstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk ModelPeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Journal of Crohn'S & Colitis|March 30, 2016
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to InfliximabKonstantinos Papamichael, Oliviane Rivals-Lerebours, Thomas Billiet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2014
A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitisMaria Theresa Arias, Niels Vande Casteele, Séverine Vermeire, et al.
Annals of Internal Medicine|December 8, 2015
Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort StudyIsabelle Cleynen, Wouter Van Moerkercke, Thomas Billiet, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
European Journal of Gastroenterology & Hepatology|February 21, 2018
The operative risk and natural history after the diagnosis of ileal penetrating Crohn's diseasePeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
European Journal of Gastroenterology & Hepatology|September 8, 2016
Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatmentLucas Wauters, Thomas Billiet, Konstantinos Papamichael, et al.
Scandinavian Journal of Gastroenterology|June 17, 2017
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's diseaseThomas Billiet, Isabelle Cleynen, Vera Ballet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of ThiopurinesHaggai Bar-Yoseph, Matti Waterman, Ronit Almog, et al.
Journal of Crohn'S & Colitis|September 10, 2015
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's DiseaseThomas Billiet, Konstantinos Papamichael, Magali de Bruyn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 19, 2015
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative ColitisKonstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk ModelPeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Journal of Crohn'S & Colitis|March 30, 2016
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to InfliximabKonstantinos Papamichael, Oliviane Rivals-Lerebours, Thomas Billiet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2014
A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitisMaria Theresa Arias, Niels Vande Casteele, Séverine Vermeire, et al.
Annals of Internal Medicine|December 8, 2015
Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort StudyIsabelle Cleynen, Wouter Van Moerkercke, Thomas Billiet, et al.
Pageof 3